


ESM accompanying the original article “Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial” by Tonneijck L et al

ESM Fig. 4 Subgroup-analyses of GFR response to intravenous GLP-1RA exenatide administration in overweight patients with type 2 diabetes



Data are shown as mean (95% confidence interval)

^aCalculated using the MDRD study equation: $186 \times (\text{serum creatinine [mg/dl]})^{-1.154} \times (\text{age [year]})^{-0.203} \times (0.742, \text{ if female})$ [1]

References

1. Myers GL, Miller WG, Coresh J, et al. (2006) Recommendations for improving serum creatinine measurement: A report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 52:5–18.